Nemolizumab, a biologic targeting interleukin-31 signaling, demonstrated enduring efficacy in managing prurigo nodularis (PN) over 68 weeks, as evidenced by a multicenter clinical trial involving 226 participants aged 13 and older. Patients treated with 30 mg or 60 mg doses reported significant reductions in peak itching and prurigo nodules compared to placebo, alongside improvements in quality of life metrics. The study highlights both the sustainability of treatment effects and the drug's tolerability, marking a significant advancement in PN management.

Source: BJD